|
Dec 18
|
5 Big Drug Stocks That May Continue to Outperform in 2024
|
|
Dec 18
|
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings
|
|
Dec 10
|
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
|
|
Dec 8
|
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
|
|
Dec 8
|
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
|
|
Dec 7
|
Why Regeneron could be the top biotech investment in 2024
|
|
Dec 7
|
Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?
|
|
Dec 7
|
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
|
|
Dec 7
|
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
|
|
Dec 6
|
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
|
|
Dec 5
|
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
|
|
Dec 4
|
EyePoint sees stock surge on AMD drug trial data
|
|
Dec 2
|
JP Morgan’s Top 15 Stock Picks for 2023 and Now
|
|
Nov 30
|
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
|
|
Nov 27
|
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
|
|
Nov 27
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
|
|
Nov 27
|
Regeneron, Sanofi to seek new Dupixent approval in US after COPD success
|
|
Nov 27
|
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
|
|
Sep 9
|
3 Unstoppable Growth Stocks to Buy Right Now
|
|
Sep 8
|
Regeneron Provides Update on Planned Chief Financial Officer Transition
|